Martin Tami Tillotson
Insider CIK 1539494 · SUPN VP of Regulatory Affairs
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2024-02-23 | 2024-02-27 | 1,250 | — | $0 | 3,750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-02-23 | 2024-02-27 | 485 | $29.06 | $14.1K | 86,933 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2024-02-23 | 2024-02-27 | 1,250 | — | $0 | 87,418 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2024-02-22 | 2024-02-26 | 750 | — | $0 | 1,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2024-02-22 | 2024-02-26 | 750 | — | $0 | 86,414 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-02-22 | 2024-02-26 | 246 | $27.94 | $6.9K | 86,168 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-01-10 | 2024-01-12 | 8,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-01-10 | 2024-01-12 | 8,000 | $9.24 | $73.9K | 93,664 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2024-01-10 | 2024-01-12 | 8,000 | $27.91 | $223.3K | 85,664 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-08-30 | 2023-09-01 | 8,100 | — | $0 | 13,900 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2023-08-30 | 2023-09-01 | 8,100 | $32.00 | $259.2K | 85,249 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-08-30 | 2023-09-01 | 8,100 | $23.99 | $194.3K | 93,349 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2023-08-25 | 2023-08-29 | 5,135 | $31.59 | $162.2K | 85,249 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-02-23 | 2023-02-27 | 5,000 | — | $0 | 5,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-02-23 | 2023-02-27 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2023-02-22 | 2023-04-12 | 750 | — | $0 | 2,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2023-02-22 | 2023-04-12 | 750 | — | $0 | 90,323 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2023-02-22 | 2023-04-12 | 289 | $38.57 | $11.1K | 90,034 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2023-02-22 | 2023-02-24 | 750 | — | $0 | 2,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2023-02-22 | 2023-02-24 | 750 | — | $0 | 90,323 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-02-16 | 2023-02-21 | 1,500 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-02-16 | 2023-02-21 | 1,500 | — | $0 | 88,720 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-01-12 | 2023-01-17 | 1,500 | — | $0 | 1,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-08-22 | 2022-08-23 | 5,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-08-22 | 2022-08-23 | 5,000 | $35.98 | $179.9K | 87,220 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-08-22 | 2022-08-23 | 5,000 | $7.90 | $39.5K | 92,220 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-08-04 | 2022-08-05 | 5,000 | — | $0 | 5,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-08-04 | 2022-08-05 | 5,000 | $7.90 | $39.5K | 92,220 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-08-04 | 2022-08-05 | 5,000 | $32.98 | $164.9K | 87,220 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-24 | 3,000 | — | $0 | 3,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-24 | 18,000 | — | $0 | 18,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-25 | 3,000 | — | $0 | 3,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-25 | 18,000 | — | $0 | 18,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2021-04-14 | 2021-04-14 | 3,125 | — | $0 | 6,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2021-04-14 | 2021-04-14 | 3,125 | $12.98 | $40.6K | 89,451 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2021-04-14 | 2021-04-14 | 3,125 | $31.98 | $99.9K | 86,326 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2021-04-13 | 2021-04-14 | 3,125 | — | $0 | 9,375 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2021-04-13 | 2021-04-14 | 3,125 | $29.98 | $93.7K | 86,326 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2021-04-13 | 2021-04-14 | 3,125 | $12.98 | $40.6K | 89,451 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2021-02-19 | 2021-02-23 | 17,000 | — | $0 | 17,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2020-02-21 | 2020-02-25 | 22,000 | — | $0 | 22,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2012-12-12 | 2012-12-13 | 37,500 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2012-12-12 | 2012-12-13 | 1,250 | — | $0 | 1,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2012-12-12 | 2012-12-13 | 9,375 | — | $0 | 28,125 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2012-12-12 | 2012-12-13 | 1,250 | $3.36 | $4.2K | 41,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2012-12-12 | 2012-12-13 | 37,500 | $1.60 | $60.0K | 40,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2012-12-12 | 2012-12-13 | 9,375 | $2.56 | $24.0K | 50,625 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | P Buy | 2012-05-04 | 2012-05-07 | 2,500 | $5.00 | $12.5K | 2,500 | SEC↗ |